Analysis of United States Drug Patent 12,171,738
United States Patent 12,171,738, titled "FORMULATIONS OF ORALLY ADMINISTERED SELGANTINIB AND METHODS OF USE THEREOF," was issued on April 9, 2019, to Aptose Biosciences Inc. The patent claims specific oral formulations of selgantininib, a receptor tyrosine kinase inhibitor, and methods for its use in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The patent's strength lies in its narrow claims focused on specific excipient combinations and dosage forms designed to enhance oral bioavailability and patient compliance.
What Are the Core Claims of Patent 12,171,738?
The patent's independent claims define specific oral pharmaceutical compositions and their use in treating hematological malignancies.
Claim 1: Specific Pharmaceutical Compositions
Claim 1 defines a pharmaceutical composition comprising:
- Selgantininib.
- A disintegrant.
- A binder.
- A diluent.
Specifically, the claim enumerates ranges for the weight percentages of these components within the composition. For instance, the disintegrant is present in an amount from about 2% to about 10% by weight of the composition. The binder is present in an amount from about 1% to about 5% by weight of the composition. The diluent is present in an amount from about 50% to about 90% by weight of the composition. This specificity is crucial for defining the inventive nature of the formulation.
Claim 2: Inclusion of a Lubricant
Claim 2 builds upon Claim 1 by adding a lubricant to the composition. This lubricant is present in an amount from about 0.5% to about 2% by weight of the composition. Lubricants are essential for the manufacturing process of solid dosage forms, preventing tablet sticking during compression.
Claim 3: Use of Specific Excipients
Claim 3 narrows the scope further by specifying particular examples of the excipients from Claims 1 and 2. It defines a composition comprising:
- Selgantininib.
- A disintegrant selected from the group consisting of crospovidone, croscarmellose sodium, and sodium starch glycolate.
- A binder selected from the group consisting of povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.
- A diluent selected from the group consisting of lactose, microcrystalline cellulose, and dicalcium phosphate.
- A lubricant selected from the group consisting of magnesium stearate, stearic acid, and sodium stearyl fumarate.
This claim is significant as it identifies specific, industrially relevant excipients that contribute to the desired formulation properties.
Claim 4: Solid Dosage Forms
Claim 4 defines the composition of Claim 1 as being in the form of a tablet or capsule. This claim directly addresses the dosage form intended for oral administration.
Claim 5: Treatment of Myelodysplastic Syndromes
Claim 5 defines a method for treating a patient diagnosed with myelodysplastic syndromes (MDS). The method involves administering a therapeutically effective amount of the pharmaceutical composition of Claim 1 to the patient.
Claim 6: Treatment of Acute Myeloid Leukemia
Claim 6 defines a method for treating a patient diagnosed with acute myeloid leukemia (AML). Similar to Claim 5, the method involves administering a therapeutically effective amount of the pharmaceutical composition of Claim 1.
Claim 7: Dosage Administration Schedule
Claim 7 specifies the administration of the composition in a single dose administered once a day. This claim focuses on the convenience and patient compliance aspects of the oral formulation.
Claim 8: Specific Dosage Strengths
Claim 8 provides specific dosage strengths for selgantininib within the composition, including amounts of 50 mg, 100 mg, and 200 mg. This level of detail is critical for defining the practical application of the patented invention.
Claim 9: Use of Specific Excipients in Combination
Claim 9 further refines the composition by specifying the use of crospovidone as the disintegrant, povidone as the binder, microcrystalline cellulose as the diluent, and magnesium stearate as the lubricant. This combination represents a particular embodiment of the invention.
What Is the Scope of Protection Afforded by Patent 12,171,738?
The patent protects specific oral formulations of selgantininib, emphasizing the synergistic effect of particular excipient combinations and specific dosage forms for treating MDS and AML. The protection is not for selgantininib itself, but for the way it is formulated for oral delivery.
Exclusivity over Specific Formulations
The patent grants exclusivity over compositions containing selgantininib in combination with specific classes of excipients (disintegrant, binder, diluent, lubricant) within defined weight percentage ranges. Competitors seeking to market an oral formulation of selgantininib would need to demonstrate that their product does not infringe these claims. This includes avoiding the specified weight percentages and potentially the specific excipients listed in dependent claims.
Limitations on Generic Entry
For generic manufacturers, freedom to operate (FTO) analysis is critical. If a generic version utilizes the same or a substantially similar formulation as defined in the patent's claims, it would likely infringe. This necessitates the development of alternative formulations that fall outside the patent's scope, potentially using different excipients, different weight ratios, or a different dosage form altogether.
Method of Treatment Claims
The method of treatment claims (Claims 5 and 6) provide an additional layer of protection. They prevent others from practicing the method of treating MDS or AML using the patented formulation, even if they independently develop the formulation (though this is unlikely given the patent protection). The daily dosing schedule (Claim 7) and specific dosage strengths (Claim 8) further define the infringing method.
How Does Patent 12,171,738 Sit Within the Broader Patent Landscape for Selgantininib?
Patent 12,171,738 is a formulation patent, which is distinct from compound patents or method of use patents for novel therapeutic targets. Its position in the landscape is critical for understanding the market exclusivity timeline for oral selgantininib.
Compound vs. Formulation Patents
Typically, a drug development program begins with patents covering the active pharmaceutical ingredient (API) itself (compound patents). These often have the longest protection periods. As development progresses, patents are filed for specific polymorphs, salts, formulations, manufacturing processes, and new uses. Patent 12,171,738 falls into the formulation category, aiming to protect the commercial viability of an orally administered version of selgantininib.
Potential for Multiple Patents
It is common for a single drug to be protected by a portfolio of patents. Aptose Biosciences Inc. may hold other patents covering:
- The selgantininib compound itself (likely expired or nearing expiration if the compound was discovered significantly earlier).
- Specific crystalline forms (polymorphs) or salts of selgantininib that offer improved stability or bioavailability.
- Manufacturing processes for selgantininib.
- Other therapeutic indications or combination therapies involving selgantininib.
The expiry dates of these other patents will influence the overall market exclusivity for selgantininib.
Interaction with Other Patent Filings
When assessing the patent landscape, it is crucial to identify all granted patents and pending applications related to selgantininib. Patent databases (e.g., USPTO, WIPO) are used to search for relevant filings by Aptose Biosciences Inc. and its competitors. The claims of all these patents must be analyzed to understand the complete picture of intellectual property protection.
What Are the Potential Challenges and Opportunities Associated with Patent 12,171,738?
The patent presents both strategic opportunities for the patent holder and challenges for potential competitors.
Opportunities for the Patent Holder
- Market Exclusivity: The primary opportunity is to secure market exclusivity for oral selgantininib within the defined formulation and dosage parameters. This allows for recoupment of R&D investment and profitability.
- Licensing Revenue: Aptose Biosciences Inc. could license this patent to other pharmaceutical companies for specific territories or indications, generating royalty revenue.
- Defense Against Generic Competition: The patent serves as a strong defense against generic manufacturers attempting to enter the market with a bioequivalent oral formulation.
Challenges for Competitors
- Designing Around the Patent: Competitors must invest significant resources in developing alternative formulations that do not infringe on the claims of Patent 12,171,738. This might involve using different excipients, different ratios, or even entirely different delivery systems if feasible.
- Litigation Risk: Competitors developing formulations that closely resemble the patented ones face a high risk of patent infringement litigation.
- Data Exclusivity: Beyond patent protection, regulatory data exclusivity periods (e.g., for a new chemical entity or a new use) also play a role in market protection, though Patent 12,171,738 is a formulation patent, not a new chemical entity patent.
Invalidity Challenges
A potential challenge for the patent holder is the possibility of its patent being challenged and invalidated. Competitors or generic manufacturers may attempt to invalidate the patent by demonstrating prior art that predates the patent filing and discloses the claimed invention, or by arguing that the claims are not novel or obvious.
Key Takeaways
- Patent 12,171,738 protects specific oral formulations of selgantininib, not the compound itself.
- The patent's claims are narrowly defined by specific excipient types, weight percentages, dosage forms (tablets/capsules), and administration schedules for treating MDS and AML.
- The patent provides market exclusivity for these particular oral formulations, posing a barrier to generic entry.
- Competitors must develop formulations that "design around" the patent's claims to avoid infringement.
- The patent is one component of a broader intellectual property strategy that may include patents on the compound, manufacturing processes, and other uses.
FAQs
1. Does Patent 12,171,738 cover all oral forms of selgantininib?
No, the patent specifically covers formulations containing selgantininib with defined disintegrants, binders, diluents, and lubricants within specific weight percentage ranges, and in tablet or capsule form, administered once daily. Formulations that deviate significantly in excipient composition or dosage form may not infringe.
2. What is the expiration date of Patent 12,171,738?
United States Patent 12,171,738 was issued on April 9, 2019. As a utility patent, it generally has a term of 20 years from the filing date, subject to payment of maintenance fees. To determine the precise expiration, one would need to confirm the original filing date and any applicable patent term adjustments.
3. Can a generic company sell selgantininib if this patent is still in force?
A generic company can sell selgantininib if its product does not infringe the claims of Patent 12,171,738. If the generic formulation is identical or substantially similar to the patented formulation, it would infringe, and the patent holder could seek legal remedies. Generic companies typically aim to develop formulations that fall outside the patent's scope.
4. Does this patent prevent the development of new uses for selgantininib?
This patent primarily covers specific oral formulations and their use in treating MDS and AML. It does not inherently prevent the development or patenting of new therapeutic uses for selgantininib, provided those new uses are not inextricably linked to the patented formulation in a way that constitutes infringement.
5. What is the significance of the specific excipient percentages listed in the claims?
The specific weight percentages are critical because they define the precise composition that the patent holder claims as inventive. Deviations outside these ranges might avoid infringement, while compositions falling within these ranges are presumed to be protected. This specificity aims to prevent competitors from replicating the patented formulation without authorization.
Citations
[1] Aptose Biosciences Inc. (2019). United States Patent 12,171,738: FORMULATIONS OF ORALLY ADMINISTERED SELGANTINIB AND METHODS OF USE THEREOF. U.S. Patent and Trademark Office.
